Stada Arzneimittel’s controlling shareholders, Bain Capital and Cinven, have made an improved €81.83 (US$94.38) per share offer to minority shareholders as they seek to take full control of the German generics and OTC specialist. The offer is a tenth higher than the previous €74.40 per share bid that failed to attract holders of 35% of Stada shares not currently held by their Nidda Healthcare vehicle (Generics bulletin, 11 May 2018, page 6).
The private-equity firms said they had received “irrevocable undertakings” from two undisclosed Stada shareholders under common control, together holding 12%...
